perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

RBDAct: Home screening of REM sleep behaviour disorder based on wrist actigraphy in Parkinson's patients.

Flavio Raschellà¹, Stefano Scafa^{2,3,4}, Alessandro Puiatti⁴, Eduardo Martin Moraud^{2,3*} and Pietro-Luca Ratti^{5*} 4 5 6 7 ¹Onera Health, 5617 BD Eindhoven, The Netherlands 8 ² Defitech Centre for Interventional Neurotherapies (.NeuroRestore), Lausanne University Hospital and Ecole 9 Polytechnique Féderale de Lausanne (EPFL), Switzerland 10 ³ Department of Clinical Neurosciences, Lausanne University Hospital (CHUV), Lausanne, Switzerland ⁴ Institute of Digital Technologies for Personalized Healthcare (MedITech), University of Applied Sciences and 11 12 Arts of Southern Switzerland, Lugano, Switzerland 13 ⁵Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland. 14 15 * These authors contributed equally to this work 16 17 Correspondence to 18 Pietro Luca Ratti 19 Neurocenter of Southern Switzerland 20 Ente Ospedaliero Cantonale 21 via Tesserete, 46 22 CH-6903 Lugano, Switzerland 23 e-mail: pietroluca.ratti@gmail.com 24 25 Word count (excluding title page, abstract, references, figures and tables): 3488

26

3

27 ABSTRACT

28

29 Background:

REM sleep behaviour disorder (RBD) is a disabling, often overlooked sleep disorder affecting up to 70% of patients with Parkinson's disease. Identifying and treating RBD is critical to prevent severe sleep-related injuries, both to patients and bedpartners. Current diagnosis relies on nocturnal video-polysomnography,

33 which is an expensive and cumbersome exam requiring specific clinical expertise.

34

35 Objectives:

To design, optimise, and validate a novel home-screening tool, termed RBDAct, that automatically identifies
 RBD in Parkinson's patients based on wrist actigraphy only.

38

39 Methods:

40 Twenty-six Parkinson's patients underwent two-week home wrist actigraphy worn on their more affected

41 arm, followed by two non-consecutive in-lab evaluations. Patients were classified as RBD versus non-RBD

42 based on dream enactment history and video-polysomnography. We characterised patients' movement

43 patterns during sleep using raw tri-axial accelerometer signals from wrist actigraphy. Machine learning

44 classification algorithms were then trained to discriminate between patients with or without RBD using

45 actigraphic features that described patients' movements. Classification performance was quantified with

46 respecteterisipical ndiagonesis resparately for in the centre of the respected and show of the used to guide clinical practice.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

47

52

48 **Results:**

49 Classification performance from in-lab actigraphic data reached an accuracy of 92.9±8.16% (sensitivity 50 94.9±7.4%, specificity 92.7±13.8%). When tested on home recordings, accuracy rose to 100% over the two-51 week window. Features showed robustness across tests and conditions.

53 **Conclusions:**

- 54 RBDAct provides reliable predictions of RBD in Parkinson's patients based on home wrist actigraphy only.
- 55 These results open new perspectives for faster, cheaper and more regular screening of sleep disorders, both 56 for routine clinical practice and for clinical trials.

57

58 Keywords: REM sleep behaviour disorder; Parkinson's disease; Actigraphy; Machine learning; Home 59 screening tool.

60

INTRODUCTION 61

62 REM sleep behaviour disorder (RBD) is a sleep disorder affecting up to 70% of patients with Parkinson's 63 disease (PD)¹. Patients with RBD exhibit movements and dream enactment behaviours during sleep which 64 can be vigorous, sometimes violent and harmful². Diagnosing and treating RBD is of pivotal importance to 65 prevent severe injuries to patients and their bedpartners.

Isolated RBD represents an early stage of PD or other synucleinopathies³, and can precede for several years 66 67 more overt clinical manifestations of these disorders⁴⁵. Its early diagnosis offers a unique window to evaluate disease-modifying effects of upcoming treatments⁶. Additionally, PD phenotypes that are associated with 68 69 RBD tend to be more aggressive and to exhibit more motor complications. They are also more often 70 accompanied by cognitive, behavioural and dysautonomic symptoms⁷. Identifying RBD in PD can thus 71 provide fundamental insights to inform clinical practice, both from a therapeutical and prognostic point of

72 view⁸.

73 RBD remains an overlooked and underrecognized phenomenon even among movement disorders specialists.

- 74 RBD diagnosis requires nocturnal video-polysomnography (VPSG)², which is a costly, time-consuming exam
- 75 that is only accessible in specialised centres and can be burdensome for patients.
- 76 Current screening tools rely on questionnaires or interviews. However, these approaches are often subjective, 77 and can either not be available for community-dwelling individuals⁹ or require the presence of a bedpartner¹⁰. 78 In Parkinson's patients, their reliability to capture RBD is not well established¹¹⁻¹³. Little progress has been 79 made in the development of objective screening tools for RBD diagnosis in everyday life settings. This would 80 be a mainstay to better understand RBD manifestations and their changes over time, and to assess treatment
- 81 efficacy during clinical trials and clinical routine⁶.
- In this study, we designed and validated a novel, wearable approach for identifying RBD automatically at 82 83 home in PD patients. We combined actigraphic technology and state-of-the-art machine learning algorithms 84 that were optimised in controlled clinical settings and translated to home environments.
- 85

PATIENTS AND METHODS 86

87 Study design and population

Ethical considerations 88

The study was conducted in the framework of the Awake & Move study^{14 15}. It was approved by the Ethics 89 90 committee of the Canton of Ticino, Switzerland (Ref. 2016-00056) and conducted in accordance with the 91 Declaration of Helsinki. Written consent was provided by all participants. Participation in this study was on a 92 voluntary basis and proposed to all patients meeting the eligibility criteria who were attending the outpatient 93 department of the Movement Disorder Unit of the Neurocenter of Southern Switzerland in Lugano, 94 Switzerland. Additional patients volunteered to participate after advertisements in the magazine of the Swiss 95 Parkinson's association, and in public conferences organised by the same association.

- 96
- 97 Inclusion and exclusion criteria

Eligibility criteria were: mild to moderate idiopathic PD (no atypical parkinsonism)¹⁶ (Hoehn & Yahr stage >1 98 and ≤ 3)¹⁷, no cognitive impairment (Mini-Mental State Examination score $\geq 26/30$)¹⁸, no active depression 99 (Beck Depression Inventory score < 14/63)¹⁹, no deep brain stimulation. 100

101 Study procedures

102 Patients' participation and workload

103 An initial recruitment visit (V0) was organised at the hospital by a senior neurologist, expert in sleep medicine 104 and movement disorders, who performed a thorough medical and neurological examination. Evaluations 105 included sleep history and the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-106 UPDRS), with the motor part (III) performed during the "on" phase in patients with motor fluctuations.

107 In each recruited patient, sleep and wake patterns were profiled by means of continuous actigraphy 108 monitoring, recorded at home over a 2-week period, coupled with an electronic sleep diary. Sleep and wake 109 routines were recorded by means of a proprietary application for tablets, SleepFit²⁰.

110 At the end of this period, a full in-lab video-polysomnography (VPSG) was performed. The times of "lights-111 out" and "lights-on" were set for each subject according to their usual bed- and wake-time schedules, 112 mirroring sleep habits of the previous 2 weeks. Habitual hypnotic medications and other psychotropic agents 113 were allowed during the subjects' participation in the study. Alcoholic, caffeinated or other stimulant beverages, as well as tobacco smoking, were not permitted 4 hours prior to bedtime. A second VPSG was 114 115 performed 7 to 14 days after the first one. Between the first and the second VPSG recordings, the patients 116 were asked to keep their routines and daily medications unchanged.

117

118 Wrist actigraphy

GENEActiv Original wrist actigraph (GENEActivTM, Activinsight Ltd., Kimbolton, Cambridgeshire, UK)²¹, worn 119 120 on the more affected arm, was employed during the 2-week home recordings. It recorded tri-axis arm accelerations (a_x, a_y, a_z) and environmental light. Signals were acquired at 40 Hz sampling frequency, to 121 maximise battery duration. In parallel to the in-lab VPSG recordings, continuous recordings of motor activity 122 were acquired using the same GENEActiv Original devices, set to record at a 100-Hz sampling frequency, 123 124 and worn on both wrists.

- 125
- 126
- 127

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

128 Video-polysomnography

VPSG recordings were performed according to the American Academy of Sleep Medicine standards^{22 23}, 129 including scalp electroencephalography, electro-oculogram, surface electro-myogram of the chin, lower 130 131 limbs electromyograms²⁴⁻²⁶, nasal and oral flow, respiratory effort sensors, pulse oximeter and 132 electrocardiogram. Synchronised digital infrared video tracks and ambient sound recordings were also 133 acquired (Fig. 1). Visual analysis of PSG recordings were performed by a trained sleep and movement disorder expert (PLR) according to standard criteria^{22 23}, taking into account previously published 134 recommendations and suggestions for sleep scoring in PD^{2 27}. 135

136

137 Clinical classification of patients with vs. without REM sleep behaviour disorder

RBD diagnosis was established based VPSG recordings from two consecutive nocturnal recordings to 138 improve diagnostic power ²⁸, and the medical history of each patient. The presence or absence of RBD was 139 established according to standard criteria². Tonic and phasic muscular activity of REM sleep without atonia 140 (RSWA) were defined according to the international scoring rules ²². To have a more refined categorisation, 141 142 we established a probability score for the presence or absence of RBD in every individual patient, based on 143 both video-PSG recordings of each patient, as follows: a) "definite RBD" (score=1): clear-cut complex dream 144 enactment behaviours and both tonic and phasic RSWA from VPSG; b) "probable RBD" (score=0.75): history 145 of complex dream enactment behaviours and both tonic and phasic RSWA, but not of complex dream 146 enactment behaviours observed at the VPSG; c) "probable no-RBD" (score=0.25): no history of dream 147 enactment behaviour and evidence of only tonic or only phasic RWSA at the VPSG; d) "definite no-RBD" 148 (score=0): no history of dream enactment behaviour and no evidence of RWSA at the VPSG; e) "doubtful 149 RBD" (score=0.5): history of dream enactment behaviour and evidence of only tonic or only phasic RWSA at 150 the VPSG; f) "doubtful no-RBD" (score=0.5): no history of dream enactment behaviour and evidence of both 151 tonic and phasic RWSA at the VPSG.

152 Each patient was then labelled as "RBD" or "no-RBD" according to the mean of the two individual VPSG 153 scores: "RBD" when the mean score > 0.5, "no-RBD" when the mean score < 0.5. Patients whose score was 154 equal to 0.5 were excluded to ensure that only patients with clear-cut diagnoses were considered. If only one 155 VPSG was available for analyses, the labelling was established based on that one only. Sleep-related 156 respiratory events and periodic limb movements (PLMs) were scored and accounted for (Table 2). We did not 157 find significant different between groups.

- 158
- 159 We used the STARD checklist when writing our report ²⁹.
- 160

Data processing 161

162 Pre-processing and features extraction

163 Tri-axial accelerometer signals were segmented for each night, defined as the periods of low illuminance (<200 lux) minus 10 minutes at the beginning and the end. Night-activity tri-axial signals were then combined 164 into a single magnitude vector $||a|| = (a_x^2, a_y^2, a_z^2)^{1/2}$, high-pass filtered (4th-order Butterworth, cut-off 165 frequency of 0.1Hz), and used to compute features about movement patterns. These features accounted for 166 167 both (i) the characteristics of isolated, single movement episodes, as well as (ii) global movement patterns 168 over the course of each night (Fig. 2A,B).

169 Movement episodes were identified through thresholding of the acceleration magnitude (threshold = 1*std). 170 We ensured that this value was never below 0.1. Consecutive episodes that were not spaced by at least 1 171 second were merged into a unique movement event. Each episode was then parameterized by quantifying

172 its duration (short: $\leq 2s$, medium: >2s & $\leq 10s$, long: >10s), magnitude (low: $\leq 3^*$ movement threshold, high:

- 173 $>3^*$ movement threshold), elapsed time since the previous event, and time to the next (close/clustered: ≤ 10 s, 174 medium: >10s & \leq 60s, far/scattered: >60s).
- 175 To capture global movement patterns, we additionally computed the rate of activity, defined as the 176 percentage of activity with magnitudes above the predefined threshold within a sliding window (length = 60177 seconds, step = 1ms). This activity rate conveys the overall amount of movement throughout the night.
- 178 We then computed a series of statistical metrics for each feature such as mean, standard deviation, skewness 179 or kurtosis.
- 180 Overall, twenty-nine features were extracted for each night recording (Supp. Table 1 and Fig. 2B). To verify 181 the degree of separability (RBD vs no-RBD patients) captured by the extracted features, we further computed 182 principal component (PC) analysis on this 29-dimensional feature representation.
- 183 Model construction

184 We tested several machine learning classification algorithms and compared their performance for 185 discriminating patients with or without RBD.

186 Prior to model building, a feature selection step was run to reduce the dimensionality of the feature space. 187 Redundant features were first removed if they were not significantly correlated to the subject group 188 (Spearman's, p>0.05). Least absolute shrinkage and selection operator (LASSO) regularisation was then 189 applied over the retained features: A ranking table was deducted from the subset of features withheld by 190 each LASSO model, computed over 4-fold cross-validation (CV) with 10 repetitions and increasing shrinkage 191 regularisation parameter. Features were ranked based on the percentage of times they were selected by a 192 model. Features selected by less than 10% of the models were discarded.

- 193 Classifiers were first built and tested on the data collected during in-lab recordings, from which we identified 194 the best model type and the subset of features to be used for subsequent home recordings. The ability of models to avoid overfitting was determined using a 4-fold CV with class stratification across folds. CV was 195 196 repeated 100 times to reduce bias in data splitting. We then compared models built from data recorded from 197 either the more affected, less affected, or dominant arm, as well as both arms. In 50% of the patients the 198 dominant arm was the more affected arm.
- 199 For home recordings, classifiers were trained on data acquired from three subjects per group (RBD and no-200 RBD) and tested on all remaining ones (N=20), with 100-time repetition to reduce bias in patient selection. 201 Classification performance was evaluated in terms of accuracy, sensitivity, and specificity. For the home 202 recordings, a receiver operating characteristic (ROC) curve was additionally computed to observe 203 classification performance depending on the class probability threshold.

204 Statistical analysis

- 205 Differences in population demographics were analysed using the Mann-Whitney U Test, except categorical 206 differences which were investigated using a Chi-squared (x2) test. The contribution of individual features to 207 help discriminate between RBD and no-RBD patients was evaluated by relating each feature score to the 208 corresponding patient label. Significance was analysed using linear mixed-effects models, with individuals as 209 random effects (to control for repeated measurements per subject). Homoscedasticity was apparent for all 210 models. Comparisons in performance between machine learning models were evaluated using the Mann-211 Whitney U Test; all results were corrected for multiple comparisons by means of Tukey-Kramer's correction. 212 All data are reported as mean values ± standard deviation (SD). Stars *,**,*** indicate a significant difference
- 213 at p < 0.05, p < 0.01 and p < 0.001 respectively.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

RESULTS 214

215 Patients' population

216 Twenty-seven PD patients were enrolled in the study. Eighteen patients were labelled as RBD and eight as no-RDB. One patient had to be excluded as their RBD probability score was 0.5, and based on one VPSG 217 218 recording only (data loss). Patients' demographic and clinical characteristics are reported in Table 1.

219 Clinical validation of RBDAct methodology

220 Extraction of features describing RBD movements and behaviours

221 We first computed mathematical features that captured nocturnal movement patterns from the acceleration 222 signals. We specifically aimed to account for both (i) the characteristics of single, isolated movement 223 episodes, and (ii) global movement patterns over the course of each night. Overall, twenty-nine features were 224 extracted, for each night (Fig. 3A). These were then matched with the corresponding clinical label (RBD vs 225 no-RBD) provided by the clinical expert for training the algorithms.

226 To verify the capacity of the identified features to capture key differences between RBD and no-RBD patients, 227 we projected the computed 29-dimensional parameterization into a low-dimensional space using PC analysis 228 (Fig. 3A). The first 3 PCs explained 79.7% of the overall variance (PC1: 51.3%, PC2: 14.9%; PC3: 13.5%), and highlighted clear differences in space between the two groups. PC1 specifically segregated patients 229 230 based on the characteristics of movement episodes, based on their duration and magnitude. A closer analysis 231 of the factor loadings of PC1 emphasised that RBD patients exhibited predominantly short, yet high-232 magnitude movement episodes that were scattered throughout the night, as reflected by the lower mean activity rate and lower percentage of clustered movements (Fig. 3B). Additionally, overall nocturnal activity 233 234 was higher in RBD than no-RBD patients.

235 We then identified the most meaningful features for classification. A feature selection step was run to extract 236 the ones that maximised the separability between groups. All selected features (N=12) exhibited (i) a high 237 correlation to the patient group (> 10%), (ii) a high occurrence in LASSO regression (> 10%), and (iii) low inter-238 feature correlation (Fig. 3C). As anticipated by the PC analysis, this set of features confirmed that group 239 separability was based on the amount of motor activity throughout the entire night, as well as episode duration 240 and magnitude.

241 In-lab RBDAct classification performance

242 To automatically discriminate RBD patients using the selected features, we compared the performance of 243 different classification algorithms. All algorithms consistently yielded a high prediction accuracy (mean 244 performance 89.6%), based on the actigraphic recordings acquired during the two nights spent by the patient 245 at the sleep lab. The best performance was achieved by a support vector machine (SVM) model ($92.9 \pm 8.16\%$ 246 accuracy, $94.9 \pm 7.4\%$ sensitivity, $92.7 \pm 13.8\%$ specificity; Fig. 3D). This model was then retained as the 247 most suitable algorithm to subsequently test home recordings.

248 We additionally explored if sensor placement had an impact on the features' ability to capture RBD patterns. 249 We compared the performance of models when the wrist actigraph was worn on the (i) more affected side, 250 (ii) less affected side, (iii) dominant side or (iv) both arms. We only considered patients who exhibited 251 asymmetric motor deficits and wore actigraphic sensors on both arms (N=16 RDB, N=5 no-RBD). Maximum 252 performance was systematically obtained using classifiers that were built on data from the more affected 253 arm, as compared to using the dominant or less affected arm (Fig. 4). Placing sensors on both wrists did not 254 improve classification performance.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

255 **RBDAct performance in home environments**

256 We then tested RBDAct at home. All the patients wore the actigraph during the whole duration of the study 257 (adherence = 100%).

258 We run our SVM algorithm using the selected features on a 2-week home recording set (Fig. 5A). We 259 computed the classification accuracy for each individual night (Fig. 5B), and derived a diagnosis from the 2-260 week probability average to account for daily variability in spontaneous occurrence of RBD movements that 261 would affect classification outcome (Fig. 5C). Setting a classification threshold between 0.5 and 0.6 revealed 262 an accuracy of 100% after 7 nights. Progressively increasing the number of nights from 7 to 14, accuracy 263 remained stable between 96 and 100%.

264

DISCUSSION 265

We developed a novel screening tool, termed RBDAct, to automatically identify RBD at home in patients with 266 267 mild to moderate PD. We first identified features that characterised differences in nocturnal movements and 268 behaviours in RBD vs. no-RBD patients from actigraphic recordings. We then trained various machine 269 learning classification algorithms using in-lab actigraphic data acquired in parallel to VPSG. Classification 270 proved to be highly accurate (92.9 ± 8.16%). Finally, we tested the performance of the best algorithm on a 271 14-night actigraphic home recording. This out-of-lab validation reached an accuracy of 100% across 272 patients.

273 Actigraphic features robustly capture RBD movements and behaviours

274 RBDAct relied exclusively on accelerometer signals to detect movements and behaviours characteristic of 275 RBD. These have been reported to be qualitatively different from controls during wakefulness, and particularly 276 during arousals and awakenings. RBD movements were reported to be faster, more abrupt, jerky, and violent, both when observed in VPSG or by patients' bedpartners ³⁰. These observations provided the ground for 277 278 using acceleration as a marker of RBD among the full range of nocturnal movements. Our automated 279 approach confirms these differences from an objective, quantitative standpoint.

280 Both global night activity patterns, and isolated movement episodes were found to be critical to discriminate 281 between RBD and no-RBD patients, regardless of the analytical methodology employed (i.e. PCA or feature selection algorithms). Features related to global night activity underscored that RBD patients were more 282 active overall, which is in line with VPSG observations ^{28 31 32}, and that they exhibited movements that were 283 284 scattered in time over the course of the night. Instead, patients without RBD moved less frequently and, if 285 they did, their movements were long-lasting and clustered in concise periods of the night. Features related 286 to isolated movement episodes showed that RBD patients exhibit predominantly short, high-magnitude 287 movements compared to no-RBD patients.

288 From a clinical standpoint, RBD movements and behaviours are expected to cluster intermittently, in correspondence to REM sleep periods. Sleep destructuring in PD ^{33 34}, with REM sleep exhibiting a non-289 nychthemeral distribution, might explain why RBD movements detected by means of actigraphy were found 290 291 to be spread over the course of the night.

292 Regardless of cross-patient differences, all tested classification algorithms systematically achieved high 293 performances, confirming the robustness of the identified features to capture key aspects of RBD movements 294 and behaviours. Similar performance was achieved during home recordings, emphasising their stability on 295 multiple observations from the same subject.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

296 Relevance of the number and location of actigraphic sensors

Maximal classification performance was achieved on average when the sensor was placed on the more affected arm, as compared to the less affected side or the dominant side. This observation suggested that abnormal movements of RBD may be more pronounced on the most affected hemibody. While this may not apply to all individual patients, our experience suggests that the most appropriate *a-priori* placement should be on the most affected arm.

Using two sensors (one per wrist) did not improve the ability to discriminate between RBD vs. no-RBD patients. In some cases, it even worsened prediction accuracy. This suggests that movements of the less affected arm are "less abnormal", thus reducing the separability between RBD and no-RBD measurements. These observations have compelling practical implications: the ability to restrict recordings to one arm simplifies the setup, increasing comfort and decreasing cost. It certainly accounts for the 100% adherence achieved during home recordings.

308 Relevance of the number of nocturnal recordings

309 Combining measurements from multiple nights proved to be essential to ensure an accurate identification of

RBD. In this study, information from VPSG recordings from two nights was necessary to confirm or rule out
 RBD diagnosis, in a few patients.

312 An average accuracy of 100% was reached after 7 consecutive nights of actigraphic home recordings. It

remained stable between 96-100% when accounting for subsequent nights. Based on these results, we

recommend that at least one week of actigraphy data be collected to maximise diagnostic accuracy.

315 Limitations and future improvements

Considering the relatively small cohort of patients (18 RBD and 8 non-RBD patients) that were included in the study, the generalisation of our approach for widespread clinical use requires further validations. Our algorithms were trained and tested only on patients with RBD that was secondary to mild or moderate PD. We did not include neither patients with RBD secondary to disorders other than PD, nor patients with isolated RBD.

- Similarly, RBDAct did not account for sleep stages in the classification pipeline. Performance may improve
 by including information about REM or NREM periods. It may be necessary to account for sleep fragmentation
 and disruption in PD and for the fact that RBD movements may not be exclusively restricted to REM phases,
 but may also appear at NREM/REM transitions during "covert REM sleep" ³⁵ or during "undifferentiated"
 sleep³⁴.
- 326 Finally, RBDAct is biased towards identifying patients with RBD characterised by phasic loss of muscle 327 atonia, as only phasic activity can be detected by accelerometers. This is nevertheless more clinically 328 meaningful than tonic RSWA in patient management, to prevent consequences such as injuries to patients 329 or bedpartners. Similarly, RBDAct may have difficulties controlling for RBD-like movements observed on 330 respiratory arousals ³⁶ or other sleep-related behaviours. The absence of a control group for these aspects 331 indicates that RBDAct may indeed lead to false positives. Considering that RBDAct is meant to provide a first screening step to guide further in-depth clinical evaluations, our methodology ensures that false negatives 332 333 are prevented, even at the expense of some false positives.

334 CONCLUSION

RBDAct is an innovative technological solution to automatically detect RBD in PD patients. Considering the
 simplicity of manipulation and affordable price of actigraphy, our approach paves the way for widespread
 screening of large numbers of patients in ecological environments, both for clinical and research purposes.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

338 Replacing in-lab VPSG with home recordings holds important implications for patients exhibiting severe 339 motor difficulties or dementia, for whom in-lab VPSG can be complex and bothersome. Its potential may also 340 be meaningful for patients who do not have a bed partner. In research, RBDAct would permit large-scale 341 screening and profiling of PD patients during clinical trials. There is a potential for rapid deployment within 342 commercially available technologies, with the advantage of being an automated procedure that is simple to 343 interpret.

344 RBDAct also has the potential to become a quantitative marker of disease severity, and could be employed 345 to monitor disease progression, to adapt symptomatic treatments, or to evaluate the efficacy of neuroprotective or disease-modifying medications. 346

347 Further developments should foresee expanding its applicability in other populations (such as isolated RBD, 348 RBD secondary to other synucleinopathies, or acute, non-degenerative RBD) and for discriminating RBD from 349 other sleep-related behaviours (such as NREM parasomnia, nocturnal epilepsy, arousals from phasic 350 respiratory events).

Acknowledgments 351

352 We would like to thank all the patients who took part in this study. Thanks to Pr. Alain Kaelin-Lang for his strategic support to the Sleep, Awake & Move project, and, together with Dr. Salvatore Galati and Dr. Claudio 353 354 Staedler, for patient recruitment.

355 We thank Mr. Paulo-Edson Nunes-Ferreira, Dr. Clara Ferlito, Dr. Sandra Hackethal, Dr. Ninfa Amato, Dr. 356 Serena Caverzasio, Dr. Simona Bonoli, Dr. Lucia Guglielmetti, Dr. Matteo Pereno, Mr. Francesco Mezzanotte 357 for data collection, and Dr. Jihad Louali and Ms. Charlotte Moerman for help with data pre-processing.

358 We also thank all the colleagues and co-workers who gave scientific, technical or logistic support to the 359 Sleep, Awake & Move project and shared our enthusiasm: Engr. Michele Marazza, Engr. Alessandro Mascheroni, Dr. Francesca Dalia Faraci, Engr. Luigi Fiorillo, Pr. Moustapha Dramé, Mr. Pierluigi Lurà, Mrs. 360 361 Nicole Vago-Caputo, Mrs. Simona Perrotta, Mr. Giuliano Filippini, Mrs. Yasmin Belloni.

- 362
- 363

Contributors 364

365 The RBDAct project was an initiative of PLR. PLR, FR, AP and EMM participated in the design of the study. 366 PLR obtained funding to support the study. PLR was responsible of patients' recruitment and screening and of data collection. FR was the study biostatistician responsible for the statistical analysis. FR, SS, PLR were 367 368 responsible for processing and analysis of data. FR and SS generated machine learning models. FR was responsible for generating the figures. PLR, AP and EMM were involved in study supervision. All authors were 369 370 involved in the interpretation of the data and in the manuscript writing. All authors agreed on the content of 371 the manuscript, reviewed drafts, and approved the final version.

Funding 373

374 The RBDAct study stemmed from the Sleep, Awake & Move project (NSI.LS15.3), that was supported by the

375 Advisory Board of EOC for Scientific Research (ABREOC) and the Swiss Parkinson's Association. EMM was

funded by the Swiss National Science Foundation (Ambizione fellowship PZ00P3_180018), 376

377

372

Competing Interests 378

379 The authors have no competing interests to declare.

Data availability statement 380

Data are available with a granted proposal upon reasonable request. 381

TABLES

Table 1 | Patient's demographic and clinical characteristics.

Characteristic	RBD (n=18)	no-RBD (n=8)	Difference p-value ¹
Age (year)	69.9±8.2	63.8±13.9	0.29
Sex (M/F)	15/3	4/4	0.07 ²
Headedness (score)	74.2±34.9	80.6±39.7	0.29
More affected side (right/left/symmetrical)	7/9/2	4/2/2	0.43
MDS-UPDRS total score	50.9±23.1	46.6±15.4	0.59
part I	8.8±5.1	10.2±4.8	0.48
part II	9.7±6.2	10.1±4.3	0.65
part III (on)	29.8±14	25.6±12.7	0.54
part IV	2.6±2.8	0.6±1.2	0.07
Hoehn & Yahr stage	2.0±0.4	1.9±0.4	0.44
Disease duration (year)	7.4±5.9	4.9±4.9	0.26
Presence of motor fluctuations (yes/no)	1/17	1/7	0.53 ²
Presence of dyskinesias (yes/no)	10/8	2/6	0.14 ²
Medications			
levodopa daily equivalent dose (mg)	589.7±275.6	655.3±333. 8	0.78
benzodiazepines (yes/no)	5/13	1/7	0.39 ²
melatonin (yes/no)	0/0	0/0	
antidepressants (yes/no)	7/11	2/6	0.49 ²
Cumulative illness rating scale - revised (score)	12.9±3.6	21.0±3.6	0.62
Cumulative illness rating scale - musculoskeletal (score)	0.9±0.8	1.4±1.1	0.25
Parkinson's disease sleep scale (score)	11.8±7.7	14.5±9.8	0.43
Pittsburgh sleep quality index (score)	5.7±2.7	6.0±2.1	0.75

Epworth sleepiness scale (score)	6/12	4/4	0.42 ²	
----------------------------------	------	-----	-------------------	--

Clinical scores taken as the average per subject over the entire study. Data are reported as mean ± SD or proportions. ¹Mann-Whitney U Test; ²Chi-squared test.

Table 2 | Video-polysomnographic features.

as mean \pm SD. ¹Mann-Whitney U Test; *P < 0.05.

Characteristic	RBD (n=18)	no-RBD (n=8)	Difference p-value ¹
Total sleep time (min)	297.5±69.3	316.0±66.0	0.56
Sleep onset latency (min)	12.0±8.2	9.5±8.2	0.52
REM onset latency (min)	177.5±61.8	201.7±132. 0	0.74
Wake after sleep onset (min)	59.5±24.1	94.3±66.5	0.19
Wake (min)	70.0±26.9	104.0±73.9	0.25
Stage N1 (min)	55.1±27.0	70.5±31.6	0.29
Stage N2 (min)	159.2±48.9	177.2±67.4	0.27
Stage N3 (min)	60.8±23.0	37.0±16.7	0.02*
REM (min)	22.5±17.0	25.6±14.9	0.56
Sleep efficiency (%)	79.7±7.1	75.8±14.5	0.8
Apnea index	35.6±25.3	41.8±19.6	0.15
Apnea-Hypopnea index	18.1±14.2	16.2±18.9	0.7
Respiratory disturbance index	30.2±26.7	33.8±25.9	0.81
Periodic limb movement	10.5±22.4	0.9±1.5	0.71

Video-polysomnographic features taken as the average per subject over the entire study. Data are reported

409 Supplementary Table 1 | Description of features

Feature	Description	Category
Activity	Percentage of overall activity	Global movement patterns
Mov number	Total number of movement episodes	
ActivityRatelow	Percentage of activity rate > 0% and \leq 30%	
ActivityRatemedium	Percentage of activity rate > 30% and $\leq 60\%$	
ActivityRate _{high}	Percentage of activity rate > 60% and $\leq 100\%$	
mean(ActivityRate)	Mean of the activity rate distribution	
median(ActivityRate)	Median of the activity rate distribution	
std(ActivityRate)	Standard deviation of the activity rate distribution	
skew(ActivityRate)	Skewness of the activity rate distribution	
kurt(ActivityRate)	Kurtosis of the activity rate distribution	
MovDistance _{close}	Percentage of movement episodes that have distance from the previous/next movement \leq 10 seconds	Movement episodes
MovDistance _{medium}	Percentage of movement episodes that have distance from the previous/next movement > 10 and \leq 60 seconds	
MovDistance _{far}	Percentage of movement episodes that have distance from the previous/next movement > 60 seconds	
MovDuration _{short}	Percentage of movement episodes that have duration ≤ 2 seconds	
MovDuration _{medium}	Percentage of movement episodes that have duration > 2 and ≤ 10 seconds	
MovDuration _{long}	Percentage of movement episodes that have duration > 10 seconds	
mean(MovDuration)	Mean of the movement duration distribution	
median(MovDuration)	Median of the movement duration distribution	

std(MovDuration)	Standard deviation of the movement duration distribution
skew(MovDuration)	Skewness of the movement duration distribution
kurt(MovDuration)	Kurtosis of the movement duration distribution
MovHighMagnitude	Percentage of movement episodes with magnitude > 3*movement threshold
MovHighMagnitudeLowDuration	Percentage of movement episodes that have duration \leq 2 seconds and magnitude > 3^* movement threshold
MovHighMagnitudeLowDistance	Percentage of movement episodes that have distance from the previous/next movement ≤ 10 seconds and magnitude > 3*movement threshold
mean(MovMagnitude)	Mean of the movement magnitude distribution
median(MovMagnitude)	Median of the movement magnitude distribution
std(MovMagnitude)	Standard deviation of the movement magnitude distribution
skew(MovMagnitude)	Skewness of the movement magnitude distribution
kurt(MovMagnitude)	Kurtosis of the movement magnitude distribution

FIGURES AND CAPTIONS 413

414

Figure 1 | Experimental setup for in-lab recordings and study design. Video-polysomnography (VPSG) 415 416 was recorded concurrently to actigraphy (1). All VPSG signals were displayed (2a) and processed by a clinical 417 expert (3a) to perform RBD diagnosis following a standard manual approach (4). In parallel, actigraphic signals 418 (2b) were processed using machine learning algorithms (3b) to generate an automatic diagnosis of RBD. The 419 study timeline displays the chronological series of recordings performed for each patient, which combined 420 both home and in-clinic evaluations.

421

422 Figure 2 Data processing methodology and feature extraction. a, The sleeping period was derived using 423 a light sensor (top), aligned with movement wrist actigraphy recordings (bottom). The night period considered 424 for analyses is shadowed in grey. b, Features of nocturnal behaviour were extracted from single movement 425 episodes (top), which characterised behaviour at well-defined isolated times throughout the night, and global 426 movement patterns (bottom).

427

428 Figure 3 | Features capturing RBD movements and behaviours. a, Representation of each patient in a 429 low-dimensional feature space (principal components PC1 to PC3). RBD patients indicated in red, and no-430 RBD patients in cyan. The contribution of each individual feature highlights the movement and behaviours that are most meaningful along PC1. Features outlined in green correspond to those shown in panel b. b, 431 432 Barplots showing group-level differences between RBD and no-RBD patients in gait features identified in a. 433 c, A feature selection algorithm identified the most discriminant features between groups using Spearman's 434 correlation and LASSO regression. d, Classification accuracy for the five machine learning algorithms 435 implemented and confusion matrix for the better performing one (SVM). LDA: linear discriminant analysis; 436 SVM: support vector machine; LR: logistic regression; NN: nearest neighbour; RF: random forest.

437

442

438 Figure 4 | Comparison of classification performance depending on actigraphy sensor position. All 439 algorithms systematically achieved better accuracies when sensors were worn on the most affected side. 440 LDA: linear discriminant analysis; SVM: support vector machine; LR: logistic regression; NN: nearest 441 neighbour; RF: random forest.

443 Figure 5 | Classification performance during home recordings. a, Heatmap of classification probabilities 444 per patient and night (left), and mean probability over the 14-night period aligned to the corresponding clinical 445 diagnosis (right). Probability values range from 0 (cyan, no-RBD) to 1 (red, RBD). b, ROC curve to identify the 446 classification threshold (between 0 and 1) that best discriminates RBD vs no-RBD patients across the 14 447 night period. A threshold of 0.5 was identified as providing the best results. c, Changes in classification 448 accuracy when accounting for multiple consecutive nights. Using 7 nights or more lead to performances 449 above 96.15% across patients (threshold = 0.5).

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

451 **BIBLIOGRAPHY**

452

453 1. Schenck CH, Boeve BF. The strong presence of REM sleep behavior disorder in PD: clinical and research 454 implications. Neurology 2011;77(11):1030-2. doi: 10.1212/WNL.0b013e31822e14d7 455 2. American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd ed. Darien, IL: 456 American Academy of Sleep Medicine 2014. 457 3. Högl B, Stefani A, Videnovic A. Idiopathic REM sleep behaviour disorder and neurodegeneration - an 458 update. Nature reviews Neurology 2018;14(1):40-55. doi: 10.1038/nrneurol.2017.157 [published 459 Online First: 2017/11/25] 4. Iranzo A, Molinuevo JL, Santamaria J, et al. Rapid-eye-movement sleep behaviour disorder as an early 460 461 marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006:5(7):572-7. 462 5. Schenck CH, Mahowald MW. REM sleep behavior disorder: clinical, developmental, and neuroscience 463 perspectives 16 years after its formal identification in SLEEP. Sleep 2002;25(2):120-38. 464 6. Videnovic A, Ju YS, Arnulf I, et al. Clinical trials in REM sleep behavioural disorder: challenges and 465 opportunities. J Neurol Neurosurg Psychiatry 2020;91(7):740-49. doi: 10.1136/jnnp-2020-322875 466 [published Online First: 2020/05/15] 467 7. Iranzo A, Santamaria J, Tolosa E. The clinical and pathophysiological relevance of REM sleep behavior 468 disorder in neurodegenerative diseases. Sleep Med Rev 2009;13(6):385-401. 469 8. Figorilli M, Marques AR, Meloni M, et al. Diagnosing REM sleep behavior disorder in Parkinson's disease 470 without a gold standard: a latent-class model study. Sleep 2020;43(7) doi: 10.1093/sleep/zsz323 471 [published Online First: 2020/04/05] 472 9. Frauscher B, Ehrmann L, Zamarian L, et al. Validation of the Innsbruck REM sleep behavior disorder 473 inventory. Mov Disord 2012;27(13):1673-8. doi: 10.1002/mds.25223 [published Online First: 474 2012/11/30] 475 10. Boeve BF, Molano JR, Ferman TJ, et al. Validation of the Mayo Sleep Questionnaire to screen for REM 476 sleep behavior disorder in a community-based sample. J Clin Sleep Med 2013;9(5):475-80. doi: 477 10.5664/jcsm.2670 [published Online First: 2013/05/16] 478 11. Stiasny-Kolster K, Sixel-Doring F, Trenkwalder C, et al. Diagnostic value of the REM sleep behavior 479 disorder screening questionnaire in Parkinson's disease. Sleep Med 2015;16(1):186-9. doi: 480 10.1016/j.sleep.2014.08.014 [published Online First: 2014/12/24] 481 12. Halsband C, Zapf A, Sixel-Doring F, et al. The REM Sleep Behavior Disorder Screening Questionnaire is 482 not Valid in De Novo Parkinson's Disease. Mov Disord Clin Pract 2018;5(2):171-76. doi: 483 10.1002/mdc3.12591 [published Online First: 2018/07/17] 484 13. Nomura T, Inoue Y, Kagimura T, et al. Validity of the Japanese version of the REM Sleep Behavior 485 Disorder (RBD) Screening Questionnaire for detecting probable RBD in the general population. 486 Psychiatry Clin Neurosci 2015;69(8):477-82. doi: 10.1111/pcn.12286 [published Online First: 487 2015/03/03] 488 14. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Sleep, Awake & Move - part I 489 (SA&M-I). 490 15. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Sleep, Awake & Move - Part II (SA&M-II) [Available from: https://clinicaltrials.gov/ct2/show/NCT02710487. 491 492 16. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a 493 clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55(3):181-4. 494 17. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17(5):427-42. 495 18. Folstein MF, Robins LN, Helzer JE. The Mini-Mental State Examination. Archives of general psychiatry 496 1983;40(7):812. 497 19. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Archives of general 498 psychiatry 1961;4:561-71. 499 20. Mascheroni A, Choe EK, Luo Y, et al. The SleepFit tablet application for home-based clinical data 500 collection in Parkinson's disease: user-centric development and usability study. Journal of Medical 501 and Internet Research: mHealth and uHealth 2021 502 21. van Hees VT, Sabia S, Anderson KN, et al. A Novel, Open Access Method to Assess Sleep Duration Using a Wrist-Worn Accelerometer. *PloS one* 2015;10(11):e0142533. doi: 503 504 10.1371/journal.pone.0142533

- 505 22. Berry RB, Albertario CL, Harding SM, et al. The AASM Manual for the Scoring of Sleep and Associated 506 Events: Rules, Terminology and Technical Specifications, Version 2.5. Darien, Illinois: American 507 Academy of Sleep Medicine, 2018.
- 23. Iber C, Ancoli-Israel S, Chesson ALJ, et al. The AASM Manual for the Scoring of Sleep and Associated 508 509 Events. Rules, Terminology and Technical Specifications. Westchester, IL: American Academy of 510 Sleep Medicine, 2007.
- 511 24. Frauscher B, Iranzo A, Hogl B, et al. Quantification of electromyographic activity during REM sleep in 512 multiple muscles in REM sleep behavior disorder. Sleep 2008;31(5):724-31.
- 513 25. Iranzo A, Frauscher B, Santos H, et al. Usefulness of the SINBAR electromyographic montage to detect 514 the motor and vocal manifestations occurring in REM sleep behavior disorder. Sleep Med 515 2011;12(3):284-8.
- 516 26. Frauscher B, Ehrmann L, Hogl B. Defining muscle activities for assessment of rapid eye movement sleep behavior disorder: from a qualitative to a quantitative diagnostic level. Sleep Med 2013;14(8):729-33. 517 518 doi: 10.1016/j.sleep.2012.09.028
- 519 27. Bliwise DL, Willians ML, Irbe D, et al. Inter-rater reliability for identification of REM sleep in Parkinson's 520 disease. Sleep 2000;23(5):671-6.
- 521 28. Cygan F, Oudiette D, Leclair-Visonneau L, et al. Night-to-night variability of muscle tone, movements, 522 and vocalizations in patients with REM sleep behavior disorder. J Clin Sleep Med 2010;6(6):551-5. 523 [published Online First: 2011/01/06]
- 29. Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: an updated list of essential items for reporting 524 525 diagnostic accuracy studies. Bmj 2015;351:h5527. doi: 10.1136/bmj.h5527 [published Online First: 526 2015/10/30]
- 527 30. Cochen De Cock V, Vidailhet M, Leu S, et al. Restoration of normal motor control in Parkinson's disease 528 during REM sleep. Brain 2007;130(Pt 2):450-6.
- 529 31. Consens FB, Chervin RD, Koeppe RA, et al. Validation of a polysomnographic score for REM sleep 530 behavior disorder. Sleep 2005;28(8):993-7. doi: 10.1093/sleep/28.8.993 [published Online First: 531 2005/10/13]
- 532 32. Gossard TR, McCarter SJ, Gorres E, et al. Quantitative REM Sleep without Atonia in Parkinson's 533 Disease and Essential Tremor. Mov Disord Clin Pract 2021;8(1):37-43. doi: 10.1002/mdc3.13112 534 [published Online First: 2021/01/12]
- 33. Diederich NJ, Vaillant M, Mancuso G, et al. Progressive sleep 'destructuring' in Parkinson's disease. A 535 536 polysomnographic study in 46 patients. Sleep Med 2005;6(4):313-8. doi: 537 10.1016/j.sleep.2005.03.011
- 538 34. Compta Y, Santamaria J, Ratti L, et al. Cerebrospinal hypocretin, daytime sleepiness and sleep 539 architecture in Parkinson's disease dementia. Brain 2009;132(Pt 12):3308-17.
- 540 35. Nielsen TA. A review of mentation in REM and NREM sleep: "covert" REM sleep as a possible 541 reconciliation of two opposing models. Behav Brain Sci 2000;23(6):851-66; discussion 904-1121.
- 542 36. Iranzo A, Santamaria J. Severe obstructive sleep apnea/hypopnea mimicking REM sleep behavior 543 disorder. Sleep 2005;28(2):203-6.







С



